# Mark Egly Foundation - Strategic Plan 2025-2030

**Document Version**: 1.0
**Last Updated**: November 7, 2025
**Owner**: Executive Team & Board of Directors
**Planning Horizon**: 5 Years (2025-2030)
**Purpose**: Define our roadmap to eliminate AATD diagnostic delays and transform patient outcomes

---

## üìã Table of Contents

1. [Executive Summary](#executive-summary)
2. [Strategic Context](#strategic-context)
3. [Strategic Goals 2025-2030](#strategic-goals-2025-2030)
4. [Year-by-Year Roadmap](#year-by-year-roadmap)
5. [Program Implementation](#program-implementation)
6. [Resource Requirements](#resource-requirements)
7. [Risk Management](#risk-management)
8. [Success Metrics](#success-metrics)

---

## Executive Summary

### Our 5-Year Vision

**By 2030, the Mark Egly Foundation will have cut AATD diagnostic delays in half (from 7-8 years to 3-4 years), established newborn screening in 10+ states, and become the leading patient advocacy organization for Alpha-1 Antitrypsin Deficiency.**

### The Challenge We're Solving

Alpha-1 Antitrypsin Deficiency (AATD) is an orphan genetic disease affecting an estimated 100,000+ diagnosed Americans and 300,000+ undiagnosed. The average diagnostic delay is 7-8 years, resulting in preventable lung damage, reduced quality of life, and early mortality.

**Mark Egly's Story**: As a PGA Member, Mark self-diagnosed his AATD after years of symptoms. His diagnostic journey revealed systemic failures: physicians don't think to test, patients don't know it exists, and policy doesn't prioritize rare diseases. Mark holds a patent (US20220160847) for repurposing AAT protein for firefighters, military personnel, and asthma patients‚Äîdemonstrating the broader potential of AATD research.

### Our Strategic Approach

We attack the problem from **four interconnected angles**:

```
‚îå‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îê
‚îÇ  EDUCATE ‚Üí Physicians + Patients + Public               ‚îÇ
‚îÇ  SUPPORT ‚Üí Financial Aid + Navigation + Community       ‚îÇ
‚îÇ  RESEARCH ‚Üí Innovation + Data + Better Tools            ‚îÇ
‚îÇ  ADVOCATE ‚Üí Policy Change + Systems Reform              ‚îÇ
‚îî‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îò
```

### 5-Year Outcomes (2025-2030)

**Education Impact**:

- ‚úÖ 50,000+ physicians trained via CME courses
- ‚úÖ 500+ medical institutions "AATD Aware" certified
- ‚úÖ National recognition as AATD education leader

**Support Impact**:

- ‚úÖ $5M+ in patient assistance distributed
- ‚úÖ 10,000+ patients served by navigation program
- ‚úÖ Alpha1Life.com: 25,000+ active community members

**Research Impact**:

- ‚úÖ AAT glucometer device commercially available
- ‚úÖ $10M+ in research funding facilitated
- ‚úÖ 5+ major research partnerships established

**Advocacy Impact**:

- ‚úÖ 10+ states adopt newborn screening for AATD
- ‚úÖ Protected status legislation introduced federally
- ‚úÖ Major insurance companies mandate AATD coverage

**Ultimate Impact**:

- ‚úÖ **Diagnostic delay reduced to 3-4 years** (from 7-8 years)
- ‚úÖ 50,000+ undiagnosed patients identified
- ‚úÖ Model for other orphan disease advocacy

---

## Strategic Context

### Where We Are Today (November 2025)

**Foundation Status**:

- ‚úÖ 501(c)(3) status: Active
- ‚úÖ Board of Directors: Forming
- ‚úÖ Website: old.markeglyfoundation.com (needs redesign)
- ‚úÖ Core asset: Mark's patent (US20220160847)
- üî∂ Funding: Bootstrapping phase
- üî∂ Staff: Founder + early team
- üî∂ Programs: Planning/pilot phase

**Market Context**:

- **AATD patient population**: 100,000 diagnosed, 300,000+ undiagnosed (US)
- **Competitive landscape**:
  - Alpha-1 Foundation (established, research-focused)
  - AlphaNet (patient support)
  - Pharma companies (augmentation therapy providers)
- **Our differentiation**:
  - Founder-driven with personal patent
  - Focus on diagnostic delay (unmet need)
  - Physician education + policy advocacy combination
  - Innovation pipeline (glucometer, rapid testing)

**Opportunity Assessment**:

- ‚úÖ **High-impact problem**: 7-8 year delay is preventable
- ‚úÖ **Underserved need**: No org focused primarily on diagnostic delay
- ‚úÖ **Policy momentum**: Rare disease advocacy growing
- ‚úÖ **Innovation potential**: Mark's patent + research partnerships
- ‚ö†Ô∏è **Funding challenge**: Orphan diseases struggle for attention
- ‚ö†Ô∏è **Awareness gap**: AATD unknown to most physicians and public

---

## Strategic Goals 2025-2030

### Goal 1: EDUCATION - Build National AATD Awareness

**Objective**: Transform AATD from an overlooked orphan disease into a condition every physician recognizes and tests for.

**5-Year Targets**:

- Train **50,000 physicians** via CME-accredited courses
- Certify **500 medical institutions** as "AATD Aware"
- Reach **50 million people** via public awareness campaigns
- Integrate AATD into **100 medical school curricula**
- Achieve **80% physician awareness** of AATD (from ~20% baseline)

**Key Programs**:

1. **CME Certification Program**: "Recognizing AATD in Primary Care"
2. **AATD Aware Seal**: Certification for medical institutions (like Fair Underwriting)
3. **Medical School Integration**: Standardized AATD curriculum
4. **Public Awareness Campaigns**: Digital + traditional media
5. **Patient Education Hub**: Comprehensive online resources

**Success Metric**: Diagnostic delay reduced to 3-4 years by 2030

---

### Goal 2: SUPPORT - Remove Barriers to Testing & Treatment

**Objective**: Ensure every AATD patient can afford testing, access treatment, and find community support.

**5-Year Targets**:

- Distribute **$5M+ in patient assistance** (testing + treatment)
- Serve **10,000+ patients** via navigation program
- Build **Alpha1Life.com** to **25,000+ active members**
- Facilitate **500+ support groups** nationwide
- Achieve **90+ NPS** (patient satisfaction)

**Key Programs**:

1. **Testing Assistance Fund**: Cover genetic testing costs
2. **Treatment Support Program**: Help pay for AAT augmentation
3. **Patient Navigation Service**: 1-on-1 guidance through healthcare system
4. **Alpha1Life.com Platform**: Online patient community
5. **Support Group Network**: Local/virtual peer support

**Success Metric**: 80% of patients report "support available when needed"

---

### Goal 3: RESEARCH - Accelerate Innovation in Testing & Treatment

**Objective**: Drive breakthrough innovations that make AATD testing faster, cheaper, and more accessible.

**5-Year Targets**:

- Bring **AAT glucometer** to market (Mark's vision)
- Facilitate **$10M+ in research funding** for AATD innovations
- Establish **5+ major research partnerships** (academic + pharma)
- Enroll **10,000+ patients** in data donation program
- Commercialize **Mark's patent** for firefighter/military applications
- Publish **50+ research papers** supported by foundation

**Key Programs**:

1. **AAT Glucometer Development**: Portable monitoring device
2. **Rapid DNA Testing**: Simplify genetic testing process
3. **Data Donation Program**: Build anonymous research database
4. **Research Grant Program**: Fund innovative AATD research
5. **Patent Commercialization**: License Mark's AAT repurposing innovations

**Success Metric**: AAT glucometer commercially available by 2028

---

### Goal 4: ADVOCACY - Change Policy to Mandate Early Detection

**Objective**: Achieve systemic policy changes that make AATD testing universal and protected.

**5-Year Targets**:

- Pass **newborn screening legislation in 10+ states**
- Secure **protected status** for AATD (federal)
- Mandate **insurance coverage** for testing/treatment (major insurers)
- Establish **occupational screening** for high-risk jobs
- Build **coalition of 50+ partner organizations**
- Generate **500M+ media impressions** on AATD advocacy

**Key Programs**:

1. **Newborn Screening Campaign**: State-by-state legislative push
2. **Protected Status Advocacy**: Federal legislation for AATD rights
3. **Insurance Coverage Mandate**: Policy requiring coverage
4. **Occupational Health Policy**: Screening for firefighters, military
5. **Coalition Building**: Unite rare disease + respiratory orgs

**Success Metric**: 10+ states with universal newborn AATD screening by 2030

---

## Year-by-Year Roadmap

### Year 1: FOUNDATION (2025-2026)

**Theme**: Build infrastructure, launch pilots, establish credibility

#### Q1-Q2 (Nov 2025 - Apr 2026): Setup Phase

**Organizational**:

- ‚úÖ Complete Board of Directors formation (3-5 members)
- ‚úÖ Establish 501(c)(3) infrastructure (accounting, compliance)
- ‚úÖ Hire Executive Director + Development Director
- ‚úÖ Create strategic partnerships MOU templates
- ‚úÖ Launch fundraising campaign ($500K Year 1 goal)

**Education**:

- Launch pilot CME course: "Recognizing AATD in Primary Care" (5 CEUs)
- Develop AATD Aware certification standards
- Create physician diagnostic toolkit
- Partner with 5 medical schools for curriculum integration

**Support**:

- Launch testing assistance fund (pilot: 100 patients)
- Develop patient navigation program framework
- Begin Alpha1Life.com platform design
- Recruit 25 support group facilitators

**Research**:

- Complete AAT glucometer feasibility study
- Establish research advisory board
- Launch data donation program (pilot: 500 patients)
- File provisional patents for additional innovations

**Advocacy**:

- Identify 10 target states for newborn screening
- Draft model legislation
- Build initial coalition (10 partner orgs)
- Launch grassroots advocacy training

#### Q3-Q4 (May 2026 - Oct 2026): Launch Phase

**Education**:

- Train 1,000 physicians via CME courses
- Certify first 10 institutions as "AATD Aware"
- Launch public awareness campaign (Phase 1)
- Publish patient education materials

**Support**:

- Serve 500 patients via testing assistance
- Launch patient navigation (100 patients)
- Soft launch Alpha1Life.com (1,000 members)
- Establish 25 support groups

**Research**:

- Award first research grants ($250K)
- Begin AAT glucometer prototype development
- Enroll 1,000 patients in data program
- Publish 5 research collaborations

**Advocacy**:

- Introduce legislation in 3 states
- Meet with 50+ legislators
- Generate 10M media impressions
- Launch petition campaign (target: 50K signatures)

**Year 1 Budget**: $500K

- Education: $150K (30%)
- Support: $125K (25%)
- Research: $100K (20%)
- Advocacy: $75K (15%)
- Operations: $50K (10%)

**Year 1 Success Metrics**:

- 1,000 physicians trained
- 500 patients assisted
- $250K research grants awarded
- 3 states with introduced legislation

---

### Year 2: SCALE (2026-2027)

**Theme**: Expand programs, prove impact, build momentum

#### Q1-Q2 (Nov 2026 - Apr 2027): Growth Phase

**Organizational**:

- Expand team to 10 full-time staff
- Open regional office (choose based on Year 1 data)
- Achieve $1.5M annual budget
- Recruit 50 active volunteers

**Education**:

- Train 5,000 physicians (cumulative: 6,000)
- Certify 50 institutions as "AATD Aware"
- Launch national public awareness campaign
- Integrate into 25 medical schools

**Support**:

- Serve 2,000 patients via testing assistance (cumulative: 2,500)
- Patient navigation serving 500 patients
- Alpha1Life.com grows to 5,000 members
- Establish 100 support groups nationwide

**Research**:

- Complete AAT glucometer prototype
- Award $1M in research grants (cumulative: $1.25M)
- Data program enrolls 3,000 patients (cumulative: 4,000)
- Establish 2 major pharma partnerships

**Advocacy**:

- Pass legislation in first 2 states ‚úÖ
- Introduce bills in 5 additional states
- Build coalition to 25 partner orgs
- Generate 50M media impressions

#### Q3-Q4 (May 2027 - Oct 2027): Momentum Phase

**Education**:

- Train 10,000 physicians (cumulative: 11,000)
- Certify 100 institutions
- Launch patient education app
- Host first annual AATD medical conference

**Support**:

- Serve 5,000 patients (cumulative: 5,000)
- Navigation serving 1,500 patients
- Alpha1Life.com: 10,000 members
- 200 active support groups

**Research**:

- Begin AAT glucometer clinical trials
- Award $2M grants (cumulative: $2.25M)
- Data program: 6,000 patients (cumulative: 7,000)
- Publish first major research findings

**Advocacy**:

- Pass legislation in 3 more states (cumulative: 5 states) ‚úÖ
- Federal protected status bill introduced
- Coalition: 40 partner orgs
- 100M media impressions

**Year 2 Budget**: $1.5M

- Education: $450K (30%)
- Support: $375K (25%)
- Research: $300K (20%)
- Advocacy: $225K (15%)
- Operations: $150K (10%)

**Year 2 Success Metrics**:

- 11,000 physicians trained
- 5,000 patients assisted
- $2.25M research grants awarded
- 5 states passed newborn screening ‚úÖ

---

### Year 3: IMPACT (2027-2028)

**Theme**: Demonstrate measurable reduction in diagnostic delay

#### Q1-Q2 (Nov 2027 - Apr 2028): Breakthrough Phase

**Organizational**:

- Team expands to 20 staff
- Annual budget: $3M
- Open second regional office
- Launch major donor program ($1M+ donors)

**Education**:

- Train 20,000 physicians (cumulative: 25,000)
- Certify 250 institutions
- 50 medical schools integrated
- National television PSA campaign

**Support**:

- Serve 10,000 patients (cumulative: 10,000)
- Navigation: 5,000 patients
- Alpha1Life.com: 15,000 members
- 400 support groups

**Research**:

- **AAT glucometer FDA approval** ‚úÖ
- Award $3M grants (cumulative: $4.25M)
- Data program: 12,000 patients (cumulative: 12,000)
- 3 pharma partnerships active

**Advocacy**:

- Pass legislation in 3 more states (cumulative: 8 states)
- Federal bill gains co-sponsors
- Coalition: 60 partner orgs
- Major insurance company mandates coverage ‚úÖ

#### Q3-Q4 (May 2028 - Oct 2028): Market Phase

**Education**:

- Train 30,000 physicians (cumulative: 30,000)
- 400 certified institutions
- Launch international education program
- Host 2nd annual conference (1,000+ attendees)

**Support**:

- Serve 15,000 patients (cumulative: 15,000)
- Navigation: 8,000 patients
- Alpha1Life.com: 20,000 members
- 500 support groups

**Research**:

- **AAT glucometer commercial launch** ‚úÖ
- Award $4M grants (cumulative: $6.25M)
- Data program: 15,000 patients
- Gene therapy trial partnership

**Advocacy**:

- 10 states with newborn screening ‚úÖ (GOAL MET)
- Federal bill passes House or Senate
- Coalition: 75 partner orgs
- 200M media impressions

**Year 3 Budget**: $3M

- Education: $900K (30%)
- Support: $750K (25%)
- Research: $600K (20%)
- Advocacy: $450K (15%)
- Operations: $300K (10%)

**Year 3 Success Metrics**:

- **Diagnostic delay reduced to 5-6 years** (measurable improvement)
- 30,000 physicians trained
- 15,000 patients assisted
- AAT glucometer on market ‚úÖ

---

### Year 4: TRANSFORMATION (2028-2029)

**Theme**: Systemic change is visible, model is proven

#### Q1-Q2 (Nov 2028 - Apr 2029): System Change Phase

**Organizational**:

- Team: 30 staff
- Budget: $5M
- National headquarters established
- International expansion planning

**Education**:

- Train 40,000 physicians (cumulative: 40,000)
- 600 certified institutions
- 100 medical schools integrated
- Global awareness campaign

**Support**:

- Serve 25,000 patients (cumulative: 25,000)
- Navigation: 12,000 patients
- Alpha1Life.com: 30,000 members
- 700 support groups (international)

**Research**:

- AAT glucometer: 10,000+ users
- Award $5M grants (cumulative: $10M+) ‚úÖ (GOAL MET)
- Data program: 20,000 patients
- Rapid DNA testing simplified

**Advocacy**:

- 15 states with newborn screening
- Federal protected status passes ‚úÖ
- All major insurers cover AATD
- Occupational screening mandates (firefighters)

#### Q3-Q4 (May 2029 - Oct 2029): Leadership Phase

**Education**:

- Train 50,000 physicians ‚úÖ (GOAL MET)
- 800 certified institutions
- Launch continuing education platform
- AATD textbook published

**Support**:

- Serve 35,000 patients (cumulative: 35,000)
- Navigation: 15,000 patients
- Alpha1Life.com: 40,000 members
- 1,000 support groups

**Research**:

- Second-generation glucometer in development
- Gene therapy trials show promise
- Data program: 25,000 patients
- 5+ pharma partnerships ‚úÖ (GOAL MET)

**Advocacy**:

- 20 states with newborn screening
- Federal bill fully implemented
- International policy model exported
- 500M media impressions

**Year 4 Budget**: $5M

- Education: $1.5M (30%)
- Support: $1.25M (25%)
- Research: $1M (20%)
- Advocacy: $750K (15%)
- Operations: $500K (10%)

**Year 4 Success Metrics**:

- **Diagnostic delay reduced to 4-5 years**
- 50,000 physicians trained ‚úÖ
- 35,000 patients assisted
- Federal protected status passed ‚úÖ

---

### Year 5: SUSTAINABILITY (2029-2030)

**Theme**: Institutionalize gains, plan for next decade

#### Q1-Q2 (Nov 2029 - Apr 2030): Institutionalization Phase

**Organizational**:

- Team: 40 staff
- Budget: $7M
- Endowment fund launched ($10M goal)
- International offices open

**Education**:

- 60,000 physicians trained
- 1,000 certified institutions
- AATD required in all medical schools
- AI-powered diagnostic tools

**Support**:

- Serve 50,000 patients (cumulative: 50,000)
- Navigation: 20,000 patients
- Alpha1Life.com: 50,000 members
- 1,500 support groups globally

**Research**:

- AAT glucometer: 50,000+ users
- $15M+ research facilitated
- Data program: 30,000 patients
- Gene therapy commercially available

**Advocacy**:

- 25 states with newborn screening
- Federal mandate under consideration
- Global AATD policy framework
- 1 billion media impressions (cumulative)

#### Q3-Q4 (May 2030 - Oct 2030): Reflection & Next Decade

**Strategic Assessment**:

- **Measure diagnostic delay**: Target 3-4 years ‚úÖ
- Evaluate all programs for impact
- Conduct external evaluation
- Plan 2030-2035 strategic plan

**Celebrate Wins**:

- Host 5-year anniversary gala
- Publish impact report
- Award inaugural Mark Egly Innovation Prize
- Launch "Next Decade" campaign

**Year 5 Budget**: $7M

- Education: $2.1M (30%)
- Support: $1.75M (25%)
- Research: $1.4M (20%)
- Advocacy: $1.05M (15%)
- Operations: $700K (10%)

**Year 5 Success Metrics**:

- **Diagnostic delay reduced to 3-4 years** ‚úÖ (PRIMARY GOAL MET)
- 60,000+ physicians trained
- 50,000+ patients assisted ‚úÖ
- 25+ states with newborn screening

---

## Program Implementation

### Education Program Details

#### CME Course: "Recognizing AATD in Primary Care"

**Course Structure** (5 CEUs):

- Module 1: AATD basics (genetics, pathology)
- Module 2: Clinical presentation & red flags
- Module 3: When to test & how to test
- Module 4: Treatment options & referral pathways
- Module 5: Case studies & malpractice risk

**Delivery Channels**:

- Online self-paced (primary)
- Live webinars (quarterly)
- In-person workshops (annual conferences)
- Medical school electives

**Pricing**:

- Free for first 10,000 physicians (foundation-funded)
- $49 per physician after (cost-recovery)
- Institution licenses: $2,500/year (unlimited staff)

**Accreditation**:

- AMA PRA Category 1 Credit‚Ñ¢
- AAFP Prescribed credit
- Nursing continuing education

#### AATD Aware Certification Program

**Certification Criteria** (for medical institutions):

1. ‚úÖ 80%+ physicians complete CME course
2. ‚úÖ AATD testing protocol in place
3. ‚úÖ Patient education materials available
4. ‚úÖ Cascade testing policy for families
5. ‚úÖ Annual AATD screening data reported

**Benefits of Certification**:

- "AATD Aware" seal for marketing
- Listed in patient-facing directory
- Reduced malpractice insurance (partnership with insurers)
- Access to foundation resources
- Quarterly best-practice webinars

**Renewal**: Annual (re-certification required)

#### Public Awareness Campaigns

**Phase 1: Digital (Years 1-2)**

- Social media campaigns (#GetTestedForAATD)
- Influencer partnerships (health advocates)
- Patient story videos
- Search engine marketing

**Phase 2: Traditional Media (Years 3-4)**

- Television PSAs
- Radio spots
- Print ads (medical journals, consumer magazines)
- Billboards in target markets

**Phase 3: Integrated (Year 5)**

- Multi-channel campaigns
- Celebrity spokespeople
- Cause marketing partnerships
- Documentary film

---

### Support Program Details

#### Testing Assistance Fund

**Eligibility**:

- Household income <300% federal poverty level OR
- Uninsured/underinsured for genetic testing OR
- Physician-recommended based on symptoms

**Coverage**:

- Genetic testing: Up to $500/test
- Confirmatory testing: Up to $200
- Cascade testing (family): Up to $300/member

**Application Process**:

- Online application (5 minutes)
- Physician attestation required
- Approval within 48 hours
- Direct payment to testing lab

**Year 1 Target**: 500 patients ($250K budget)
**Year 5 Target**: 10,000 patients/year ($5M budget)

#### Patient Navigation Program

**Service Model**:

- 1-on-1 personalized support
- Assigned navigator (RN or social worker)
- Support from diagnosis through treatment initiation
- Average 6-month engagement

**Navigation Services**:

- Healthcare system guidance
- Insurance navigation
- Treatment option education
- Financial assistance connections
- Emotional support
- Cascade testing coordination

**Staffing**:

- Year 1: 2 navigators (50 patients each)
- Year 5: 20 navigators (1,000 patients/year capacity)

**Metrics**:

- Time to first treatment
- Patient satisfaction (NPS)
- Treatment adherence
- Quality of life improvements

#### Alpha1Life.com Platform

**Platform Features**:

- Discussion forums (moderated)
- Expert Q&A (monthly AMA with physicians)
- Resource library
- Event calendar (support groups)
- Personal health tracking
- Peer matching (connect with similar patients)
- Caregiver community

**Content Strategy**:

- Daily: User-generated content
- Weekly: Expert articles
- Monthly: Webinars and AMAs
- Quarterly: Research updates

**Moderation**:

- Professional community manager
- Volunteer patient moderators
- Medical advisory oversight
- Clear community guidelines

**Monetization**: Free (foundation-funded)

---

### Research Program Details

#### AAT Glucometer Development

**Device Vision**:

- Portable, finger-stick device
- Measures AAT levels in real-time
- Similar user experience to glucose meters
- Bluetooth-enabled (syncs to app)
- Under $100 device, $2/test strip

**Development Timeline**:

- Year 1: Feasibility study + prototype
- Year 2: Engineering + testing
- Year 3: FDA approval process
- Year 4: Commercial launch
- Year 5: Scale + second-generation

**Partners**:

- Medical device company (manufacturer)
- Academic research lab (validation)
- AATD patients (beta testing)

**Business Model**:

- Foundation retains IP
- License to manufacturer
- Royalties fund future research
- Subsidized pricing for uninsured

#### Research Grant Program

**Grant Categories**:

1. **Innovation Grants** ($50K-$250K): Novel testing/treatment approaches
2. **Early Career Grants** ($25K-$50K): Support emerging researchers
3. **Data Grants** ($10K-$25K): Use foundation's data repository
4. **Pilot Grants** ($5K-$10K): Seed funding for preliminary studies

**Review Process**:

- Scientific advisory board review
- Patient advocate input
- Quarterly award cycles
- Public reporting of all grants

**Priorities**:

- Diagnostic delay reduction
- Testing innovations
- Quality of life improvements
- Health equity research

**Year 1 Budget**: $250K
**Year 5 Budget**: $3M/year

#### Anonymous Data Donation Program

**Program Structure**:

- Patients donate health data (de-identified)
- Tax-deductible donation (novel approach)
- Data used for research
- Aggregate findings shared publicly

**Data Collected**:

- Genetic information
- Diagnostic journey timeline
- Treatment history
- Quality of life surveys
- Longitudinal outcomes

**Privacy & Security**:

- HIPAA-compliant infrastructure
- De-identification protocols
- Institutional IRB approval
- Annual security audits

**Incentives**:

- Tax deduction (pioneering model)
- Access to aggregate research findings
- Contribution to scientific knowledge
- Optional research result notifications

---

### Advocacy Program Details

#### Newborn Screening Campaign

**State Selection Criteria**:

- Rare disease advocacy history
- Legislative champions identified
- Patient population density
- Political feasibility

**Campaign Components**:

1. **Grassroots Advocacy**: Patient stories, letter campaigns
2. **Legislative Strategy**: Bill drafting, sponsor recruitment
3. **Coalition Building**: Partner with rare disease orgs
4. **Media Relations**: Press conferences, op-eds
5. **Expert Testimony**: Medical professionals, patients

**Model Legislation**:

- Add AATD to Recommended Uniform Screening Panel
- State funding for screening program
- Follow-up protocols for positive results
- Family notification and cascade testing

**Target States** (Year 1-5):

- **High Priority**: States with champions (3-5 states)
- **Medium Priority**: States with rare disease momentum (5-10 states)
- **Long-term**: All 50 states (10-year goal)

#### Protected Status Advocacy

**Federal Legislation Goals**:

- Designate AATD as "protected genetic condition"
- Prevent insurance discrimination
- Mandate coverage for testing and treatment
- Occupational protections (firefighters, military)

**Legislative Strategy**:

- Identify bipartisan champions
- Build broad coalition support
- Leverage economic argument (early detection saves money)
- Patient advocate fly-ins to DC

**Timeline**:

- Year 1-2: Draft legislation, recruit sponsors
- Year 3-4: Build momentum, committee hearings
- Year 5: Passage goal

#### Insurance Coverage Mandate

**Approach**:

- Direct negotiations with major insurers
- Model policy language
- Economic data on cost-effectiveness
- Pilot programs with willing insurers

**Target Insurers**:

- UnitedHealthcare
- Anthem
- Aetna
- Cigna
- Humana

**Coverage Goals**:

- Genetic testing (no prior authorization)
- AAT augmentation therapy
- Monitoring (including glucometer)
- Pulmonary rehabilitation

---

## Resource Requirements

### Funding Strategy

**5-Year Funding Goal**: $17M cumulative

```
Year 1 (2025-26): $500K
Year 2 (2026-27): $1.5M
Year 3 (2027-28): $3M
Year 4 (2028-29): $5M
Year 5 (2029-30): $7M
‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ
TOTAL:            $17M
```

#### Revenue Sources

**Major Gifts** (40% - $6.8M):

- Individual donors: $5M
- Family foundations: $1.5M
- Major donor society ($100K+ gifts): $300K

**Grants** (30% - $5.1M):

- Federal grants (NIH, CDC): $2M
- Private foundations: $2.5M
- Corporate grants: $600K

**Events** (10% - $1.7M):

- Annual gala: $1M
- Golf tournaments: $500K
- Community events: $200K

**Earned Revenue** (15% - $2.55M):

- Patent licensing (Mark's IP): $1.5M
- CME course fees: $500K
- Glucometer royalties: $400K
- Consulting services: $150K

**Other** (5% - $850K):

- Planned giving: $400K
- Corporate sponsorships: $300K
- Merchandise: $100K
- Interest income: $50K

### Staffing Plan

**Year 1** (4 staff):

- Executive Director
- Development Director
- Program Manager
- Administrative Coordinator

**Year 2** (10 staff):

- +Medical Education Director
- +Patient Services Director
- +Research Director
- +Advocacy Director
- +2 Patient Navigators
- +Communications Manager

**Year 3** (20 staff):

- +Regional Directors (2)
- +Grant Manager
- +4 Patient Navigators
- +Data Manager
- +Community Manager
- +2 Program Coordinators

**Year 4** (30 staff):

- +Chief Operating Officer
- +Chief Medical Officer
- +6 Patient Navigators
- +2 Research Associates
- +2 Advocacy Managers

**Year 5** (40 staff):

- +Chief Development Officer
- +8 Regional/Program Staff
- +2 Data Scientists

**Total Payroll Budget**:

- Year 1: $300K
- Year 2: $750K
- Year 3: $1.5M
- Year 4: $2.5M
- Year 5: $3.5M

### Infrastructure Requirements

**Technology**:

- Website redesign: $100K (Year 1)
- Alpha1Life.com platform: $250K (Year 1-2)
- CRM/database: $50K setup + $20K/year
- Data infrastructure: $150K (Year 2-3)

**Physical Space**:

- Year 1: Co-working space ($1K/month)
- Year 2: Small office ($3K/month)
- Year 3: Headquarters ($8K/month)
- Year 4-5: Regional offices ($15K/month total)

**Legal/Compliance**:

- Legal counsel: $50K/year
- Accounting/audit: $30K/year
- Insurance: $25K/year
- Regulatory compliance: $20K/year

---

## Risk Management

### Risk 1: Funding Shortfalls

**Likelihood**: High (Year 1-2), Medium (Year 3-5)
**Impact**: Critical

**Mitigation Strategies**:

1. **Diversified revenue**: Don't rely on single source
2. **Phased approach**: Scale programs based on funding
3. **Cost controls**: Lean operations, maximize volunteer support
4. **Reserve fund**: Build 6-month operating reserve by Year 3
5. **Contingency plans**: Prioritize high-impact programs if cuts needed

**Scenario Planning**:

- **Best case** (110% of goal): Accelerate timeline
- **Base case** (100% of goal): Execute as planned
- **Downside** (75% of goal): Scale back support/research, maintain education/advocacy
- **Worst case** (50% of goal): Focus only on education, pause other programs

---

### Risk 2: Physician Adoption

**Likelihood**: Medium
**Impact**: High

**Risk**: Physicians don't change behavior despite education

**Mitigation Strategies**:

1. **Incentives**: Tie to malpractice insurance discounts
2. **Ease of use**: Make testing/protocols turnkey
3. **Peer influence**: Leverage early adopters as champions
4. **Measurement**: Track behavior change, adapt approach
5. **Systems focus**: Work with institutions, not just individuals

**Early Warning Signs**:

- Low CME enrollment
- Physicians complete course but don't test more
- Certification program has few applicants

**Pivot Options**:

- Focus on policy mandates (required testing protocols)
- Target high-volume institutions vs. individual physicians
- Simplify testing process further

---

### Risk 3: Innovation Delays

**Likelihood**: Medium-High
**Impact**: Medium

**Risk**: AAT glucometer takes longer/costs more than expected

**Mitigation Strategies**:

1. **Phased development**: Prototype ‚Üí validation ‚Üí FDA ‚Üí launch
2. **Expert partners**: Work with established device companies
3. **Parallel paths**: Pursue multiple innovations simultaneously
4. **Realistic timelines**: Build in buffer for setbacks
5. **Alternative revenue**: Don't rely solely on glucometer royalties

**Contingency**:

- If glucometer delayed: Focus on rapid DNA testing simplification
- If too expensive: Seek grant funding for R&D
- If technical hurdles: Partner with larger medical device firm

---

### Risk 4: Policy Setbacks

**Likelihood**: Medium
**Impact**: Medium

**Risk**: Newborn screening legislation stalls or fails

**Mitigation Strategies**:

1. **State-by-state approach**: Don't need all 50 immediately
2. **Bipartisan strategy**: Make it non-partisan issue
3. **Coalition strength**: United front with other rare diseases
4. **Patient stories**: Humanize the issue
5. **Economic argument**: Early detection saves healthcare dollars

**Alternative Approaches**:

- If state legislation fails: Focus on voluntary hospital screening
- If federal bill stalls: Pursue regulatory pathway (CDC, NIH)
- If policy route blocked: Focus on medical system change

---

### Risk 5: Competition

**Likelihood**: Low-Medium
**Impact**: Low-Medium

**Risk**: Established orgs (Alpha-1 Foundation, AlphaNet) expand into our space

**Mitigation Strategies**:

1. **Differentiation**: Focus on diagnostic delay (our unique niche)
2. **Collaboration**: Partner rather than compete
3. **Innovation**: Our IP (Mark's patent, glucometer) creates moat
4. **Founder story**: Mark's personal journey is unique asset
5. **Speed**: Move fast to establish leadership

**Competitive Advantages**:

- ‚úÖ Founder-driven with personal patent
- ‚úÖ Focus on prevention (not just treatment)
- ‚úÖ Physician education + policy combined
- ‚úÖ Innovation pipeline

---

## Success Metrics

### Primary Impact Metric

```
‚îå‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îê
‚îÇ  DIAGNOSTIC DELAY TIME (years)                          ‚îÇ
‚îÇ                                                         ‚îÇ
‚îÇ  Baseline (2025): 7-8 years                             ‚îÇ
‚îÇ  Year 1 (2026):   7-8 years (infrastructure building)   ‚îÇ
‚îÇ  Year 2 (2027):   6-7 years (early programs scaling)    ‚îÇ
‚îÇ  Year 3 (2028):   5-6 years (measurable improvement)    ‚îÇ
‚îÇ  Year 4 (2029):   4-5 years (systemic change visible)   ‚îÇ
‚îÇ  Year 5 (2030):   3-4 years ‚úÖ (GOAL ACHIEVED)          ‚îÇ
‚îÇ                                                         ‚îÇ
‚îÇ  Measurement: Annual survey of newly diagnosed patients ‚îÇ
‚îî‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îò
```

### Dashboard Metrics (Tracked Quarterly)

#### Education Metrics

- ‚úÖ Physicians trained (cumulative)
- ‚úÖ Institutions certified "AATD Aware"
- ‚úÖ Medical schools with integrated curriculum
- ‚úÖ Public awareness (survey-based)

#### Support Metrics

- ‚úÖ Patients served (financial assistance)
- ‚úÖ Navigation program participants
- ‚úÖ Alpha1Life.com active members
- ‚úÖ Support groups active
- ‚úÖ Patient satisfaction (NPS)

#### Research Metrics

- ‚úÖ Research funding facilitated
- ‚úÖ AAT glucometer development stage
- ‚úÖ Data donation participants
- ‚úÖ Research partnerships
- ‚úÖ Publications supported

#### Advocacy Metrics

- ‚úÖ States with newborn screening passed
- ‚úÖ Federal legislation progress
- ‚úÖ Insurance companies covering AATD
- ‚úÖ Coalition partners
- ‚úÖ Media impressions

#### Financial Metrics

- ‚úÖ Total revenue vs. goal
- ‚úÖ Expense ratio (program vs. overhead)
- ‚úÖ Months of operating reserve
- ‚úÖ Donor retention rate

#### Organizational Metrics

- ‚úÖ Staff count
- ‚úÖ Volunteer hours
- ‚úÖ Board engagement
- ‚úÖ Partner satisfaction

---

## Strategic Plan Governance

### Review & Adaptation

**Quarterly Reviews**:

- Leadership team assesses progress vs. milestones
- Dashboard metrics reviewed
- Risks reassessed
- Tactical adjustments made

**Annual Strategic Review**:

- Board-level assessment of strategic plan
- External stakeholder input
- Budget reallocation if needed
- Year-ahead planning

**Mid-Point Evaluation** (Year 3):

- External evaluation commissioned
- Theory of change validation
- Program effectiveness assessment
- Strategic plan revision if needed

### Success Celebration

**When We Hit Milestones**:

- Share wins with community
- Recognize staff/volunteers
- Celebrate patient stories
- Build momentum for next phase

**When We Miss Targets**:

- Honest assessment of why
- Learn and adapt
- Communicate transparently
- Recommit to mission

---

## Conclusion: Our 5-Year Commitment

The Mark Egly Foundation commits to an ambitious but achievable goal: **cut AATD diagnostic delays in half by 2030**. We will do this by:

‚úÖ **Educating** 50,000+ physicians and millions of patients
‚úÖ **Supporting** 50,000+ patients with financial aid and navigation
‚úÖ **Researching** innovations like the AAT glucometer and simplified testing
‚úÖ **Advocating** for policy changes in 10+ states and federally

**We will measure our success** not by dollars raised or programs launched, but by **lives saved through earlier diagnosis**.

**This strategic plan is our roadmap**, but we remain flexible to adapt as we learn. We are committed to evidence-based decision-making, transparent operations, and patient-first values.

**By 2030, AATD will no longer be an overlooked orphan disease.** It will be a condition every physician recognizes, every patient can access support for, and policy protects.

**This is Mark's vision. This is our commitment.**

---

**Approved by**: Mark Egly Foundation Board of Directors
**Effective Date**: November 7, 2025
**Review Date**: November 2026 (annual) / November 2027 (mid-point)
**Version**: 1.0

---

_"In 5 years, we will look back and say: this is when everything changed for AATD patients."_

**‚Äî Mark Egly Foundation Strategic Planning Team**
